UNCY FY2025 EPS Boosted by Brookline Capital Management

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Analysts at Brookline Capital Management boosted their FY2025 earnings per share estimates for shares of Unicycive Therapeutics in a research report issued to clients and investors on Wednesday, November 12th. Brookline Capital Management analyst K. Raja now forecasts that the company will post earnings per share of ($1.51) for the year, up from their previous estimate of ($1.68). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ Q4 2025 earnings at ($0.68) EPS, FY2026 earnings at ($1.75) EPS, FY2027 earnings at $8.83 EPS, FY2028 earnings at $8.66 EPS and FY2029 earnings at $8.26 EPS.

Several other brokerages also recently commented on UNCY. Wall Street Zen upgraded shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, November 2nd. Benchmark raised their price objective on shares of Unicycive Therapeutics to $21.00 and gave the stock a “speculative buy” rating in a report on Monday, September 15th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective (up from $9.00) on shares of Unicycive Therapeutics in a research report on Wednesday, October 29th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Unicycive Therapeutics in a report on Thursday, October 30th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.33.

Unicycive Therapeutics Price Performance

NASDAQ:UNCY opened at $5.92 on Monday. The business’s 50-day simple moving average is $4.59 and its 200-day simple moving average is $5.05. Unicycive Therapeutics has a fifty-two week low of $3.71 and a fifty-two week high of $11.00. The stock has a market capitalization of $127.22 million, a PE ratio of -1.50 and a beta of 1.87.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its earnings results on Wednesday, November 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.20.

Institutional Trading of Unicycive Therapeutics

A number of institutional investors have recently made changes to their positions in UNCY. Lazard Asset Management LLC bought a new position in Unicycive Therapeutics in the second quarter valued at $55,000. JPMorgan Chase & Co. boosted its stake in shares of Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after buying an additional 21,525 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Unicycive Therapeutics during the 3rd quarter worth about $182,000. Squarepoint Ops LLC bought a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at about $512,000. Finally, Vanguard Group Inc. increased its position in shares of Unicycive Therapeutics by 8.7% in the third quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after acquiring an additional 52,925 shares during the last quarter. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.